HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by White, C. M. Articles by Coleman, C. I. Search for Related Content PubMed PubMed Citation Articles by White, C. M. Articles by Coleman, C. I. Related Collections Cardiac - pharmacology

Eur J Cardiothorac Surg 2007;31:817-820. doi:10.1016/j.ejcts.2007.02.010
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved

Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III

^a University of Connecticut School of Pharmacy, Storrs, CT, United States
^b University of Connecticut School of Medicine, Farmington, CT, United States
^c Divisions of Drug Information and Cardiology, Hartford Hospital, Hartford, CT, United States

Received 12 October 2006; received in revised form 20 December 2006; accepted 12 February 2007.

^_* Corresponding author. Address: Pharmacoeconomics and Outcomes Studies Group, Hartford Hospital, 80 Seymour Street, CB309, Hartford, CT 06102, United States. Tel.: +1 860 545 2096; fax: +1 860 545 2277. (Email: ccolema{at}harthosp.org).

Background: Two recent meta-analyses demonstrated that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reduce the risk of developing new-onset atrial fibrillation (AF) by nearly 50%. However, the ability of ACEIs or ARBs to prevent postoperative atrial fibrillation (POAF) after cardiac surgery has not been adequately evaluated. Objective: To evaluate the impact of preoperative ACEI or ARB use on the incidence of POAF after cardiac surgery. Methods: Patients undergoing coronary artery bypass grafting and/or valvular surgery from the (atrial fibrillation suppression trials II and III (AFIST II and III) randomized, controlled trials were evaluated in this cohort evaluation. Data in respect to patient demographics, surgical characteristics, medication utilization and the incidence of POAF (defined as AF lasting at least 5 min in duration documented by telemetry) were all uniformly and prospectively collected as part of AFIST II and III. Multivariate logistic regression was utilized to calculate adjusted odds ratios with 95% confidence intervals. Results: A total of 338 patients were evaluated of which 175 (51.8%) received an ACEI or ARB preoperatively and 163 (48.2%) did not. The study population was 65.7 ± 9.1 years of age, 77.8% were male, 11.2% underwent valve surgery, 3.6% had prior AF, 10.1% had heart failure and 84.0 and 37.9% received postoperative beta-blockade and prophylactic amiodarone, respectively. In total, 110 (32.5%) patients developed POAF. Upon multivariate logistic regression, the preoperative use of an ACEI or ARB was not found to be associated with a statistically significant reduction in POAF (adjusted odds ratio; 0.71, 95% CIs 0.42–1.20). Conclusions: Although preoperative ACEI or ARB use reduced the odds of developing POAF by 29%, this association with not found to be statistically significant. A study with approximately 600 subjects would be needed to discern if ACEIs or ARBs truly impact POAF.

Key Words: Postoperative atrial fibrillation • Renin-angiotensin-system • Cardiac surgery

This article has been cited by other articles:

				A. Miceli, R. Capoun, C. Fino, P. Narayan, A. J. Bryan, G. D. Angelini, and M. Caputo Effects of Angiotensin-Converting Enzyme Inhibitor Therapy on Clinical Outcome in Patients Undergoing Coronary Artery Bypass Grafting J. Am. Coll. Cardiol., November 3, 2009; 54(19): 1778 - 1784. [Abstract] [Full Text] [PDF]

				M. Tavakol, K. Z. Hassan, R. K. Abdula, W. Briggs, C. E. Oribabor, A. J. Tortolani, T. J. Sacchi, L. Y. Lee, and J. F. Heitner Utility of brain natriuretic peptide as a predictor of atrial fibrillation after cardiac operations. Ann. Thorac. Surg., September 1, 2009; 88(3): 802 - 807. [Abstract] [Full Text] [PDF]

				O. J. Liakopoulos, Y.-H. Choi, E. W. Kuhn, T. Wittwer, M. Borys, N. Madershahian, G. Wassmer, and T. Wahlers Statins for prevention of atrial fibrillation after cardiac surgery: A systematic literature review J. Thorac. Cardiovasc. Surg., September 1, 2009; 138(3): 678 - 686. [Abstract] [Full Text] [PDF]

				D. Kaireviciute, A. Aidietis, and G. Y.H. Lip Atrial fibrillation following cardiac surgery: clinical features and preventative strategies Eur. Heart J., February 2, 2009; 30(4): 410 - 425. [Abstract] [Full Text] [PDF]

				P. Dorian and B. N. Singh Upstream therapies to prevent atrial fibrillation Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H11 - H31. [Abstract] [Full Text] [PDF]

				S. G. Raja ACE inhibitors as antifibrotic agents in atrial fibrillation: potential relevance in cardiac surgery Interactive CardioVascular and Thoracic Surgery, June 1, 2008; 7(3): 476 - 476. [Full Text] [PDF]

				A. Kourliouros, A. De Souza, N. Roberts, A. Marciniak, A. Tsiouris, O. Valencia, J. Camm, and M. Jahangiri Dose-Related Effect of Statins on Atrial Fibrillation After Cardiac Surgery Ann. Thorac. Surg., May 1, 2008; 85(5): 1515 - 1520. [Abstract] [Full Text] [PDF]

				K. I. Paraskevas Applications of statins in cardiothoracic surgery: more than just lipid-lowering Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 377 - 390. [Abstract] [Full Text] [PDF]